Santen Pharmaceutical Co's market cap is currently $539.17B. The company's EPS TTM is ¥73.711; its P/E ratio is 21.10; and it has a dividend yield of 2.30%. Santen Pharmaceutical Co is scheduled to report earnings on February 6, 2025, and the estimated EPS forecast is ¥26.11. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
Income Statement
Total Revenue	¥ 301.96B	¥ 279.04B	¥ 266.26B	¥ 249.60B	¥ 241.56B
Gross Profit	¥ 163.88B	¥ 166.09B	¥ 156.59B	¥ 151.38B	¥ 146.72B
Operating Income	¥ 38.54B	¥ -3.09B	¥ 35.89B	¥ 12.92B	¥ 33.53B
EBITDA	¥ 56.46B	¥ 14.30B	¥ 54.52B	¥ 30.01B	¥ 49.41B
Net Income	¥ 26.64B	¥ -14.95B	¥ 27.22B	¥ 6.83B	¥ 23.62B
Balance Sheet
Cash & Short-Term Investments	¥ 94.96B	¥ 58.68B	¥ 84.31B	¥ 63.41B	¥ 91.88B
Total Assets	¥ 435.70B	¥ 421.18B	¥ 459.98B	¥ 402.35B	¥ 408.77B
Total Debt	¥ 35.16B	¥ 36.21B	¥ 32.93B	¥ 10.15B	¥ 12.33B
Net Debt	¥ -59.42B	¥ -21.70B	¥ -50.08B	¥ -52.74B	¥ -79.10B
Total Liabilities	¥ 130.33B	¥ 127.88B	¥ 123.13B	¥ 95.30B	¥ 106.21B
Stockholders' Equity	¥ 306.06B	¥ 293.98B	¥ 337.49B	¥ 307.58B	¥ 302.87B
Cash Flow
Free Cash Flow	¥ 61.96B	¥ 12.56B	¥ 10.20B	¥ 15.00B	¥ 30.72B
Operating Cash Flow	¥ 72.65B	¥ 37.15B	¥ 46.04B	¥ 38.81B	¥ 39.95B
Investing Cash Flow	¥ -6.14B	¥ -26.78B	¥ -35.17B	¥ -53.35B	¥ -5.17B
Financing Cash Flow	¥ -34.03B	¥ -37.22B	¥ 5.56B	¥ -16.68B	¥ -12.73B

Currency in JPY

Santen Pharmaceutical Co Earnings and Revenue History

Income Statement >

Santen Pharmaceutical Co Debt to Assets

Balance Sheet >

Santen Pharmaceutical Co Cash Flow

Cash Flow >

Santen Pharmaceutical Co Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing